WAM
ENGN icon

Wolverine Asset Management’s enGene Therapeutics ENGN Stock Holding History

Wolverine Asset Management’s Portfolio ENGN Stock Details ENGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-6,361
Closed -$23.2K – 1668
2025
Q2 		$23.2K Buy
+6,361
New +$23.9K ﹤0.01% 1297
2024
Q4 		– Sell
-5,574
Closed -$36.8K – 1668
2024
Q3 		$36.8K Buy
+5,574
New +$41.5K ﹤0.01% 1210

Other funds holding ENGN

FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Wolverine Asset Management's ENGN Position: Q3 2025 in Review

Wolverine Asset Management sold out of enGene Therapeutics (ENGN) in Q3 2025, closing a stake of 6,361 shares — an estimated $23.2K sold.

Wolverine Asset Management first reported a position in ENGN in Q3 2024 and held it in 2 quarters. The position peaked at $36.8K in Q3 2024. 37 funds tracked by Wall St. Rank hold ENGN as of Q3 2025.

  • Wolverine Asset Management reported no remaining enGene Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Wolverine Asset Management sold 6,361 enGene Therapeutics shares in Q3 2025, an estimated $23.2K.
  • Wolverine Asset Management first reported a position in enGene Therapeutics in Q3 2024 and held it in 2 quarters.
  • Wolverine Asset Management's enGene Therapeutics position peaked at $36.8K in Q3 2024.
  • 37 funds tracked by Wall St. Rank held enGene Therapeutics as of Q3 2025.

Based on Wolverine Asset Management's 13F filing for Q3 2025, filed 28 Oct 2025.